Hallal David
Chief Executive Officer at SRRK; Director at ITOS; Director, 10% owner at ALVR, and 1 more
- Sold, on record
- $65.9M
- Dollars the filings state
- Form 4 sales
- 63
- Latest Apr 16, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- SRRKScholar Rock Holding CorpChief Executive Officer
- ITOSiTeos Therapeutics, Inc.Director
- ALVRAllovir, Inc.Director, 10% owner
- ALEXION PHARMACEUTICALS INCCEO
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ALVR1.2M shares
- ALEXION PHARMACEUTICALS INC468,444 shares
- ITOS194,297 shares
- SRRK88,065 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ALVRUnusualJun 3 2022
Sold 65,725 shares at $3.67 ($241k)
Hallal David, Director, 10% owner
Sold 3.1% of holdings ($7.9M position)2.1M shares left3.8x usual sizeFiling
- 2 Form 4 sale ITOSUnusualJun 9 +6 days
Sold 29,615 shares at $20.17 ($597k)
Hallal David, Director
Sold 100% of holdings ($597k position)0 shares leftFiling
- 3 Form 4 sale ALVRPlan not statedJul 21 +42 days
Sold 4,227 shares at $5.33 ($23k)
Hallal David, Director, 10% owner
Sold 0.2% of holdings ($11.1M position)2.1M shares left0.1x usual sizeFiling
- 4 Form 4 sale ALVRUnusualSep 29 +70 days
Sold 400,000 shares at $7.35 ($2.9M)
Hallal David, Director, 10% owner
Sold 35.7% of holdings ($8.2M position)720,965 shares left23.4x usual sizeFiling
- 5 Form 4 sale ALVRUnusualOct 19 +20 days
Sold 600,000 shares at $8.45 ($5.1M)
Hallal David, Director, 10% owner
Sold 81.3% of holdings ($6.2M position)138,153 shares left14.5x usual sizeFiling
- 6 Form 4 sale ITOSRoutineJun 6 +961 days
Sold 114,682 shares at $10.15 ($1.2M)
Hallal David, Director
10b5-1 planSold 100% of holdings ($1.2M position)0 shares leftFirst sale on recordFiling
- 7 Form 4 sale SRRKNo planJan 13 +221 days
Sold 57,450 shares at $42.70 ($2.5M)
Hallal David, Chief Executive Officer
No 10b5-1 planSold 3.6% of holdings ($68.3M position)1.5M shares leftFirst sale on recordFiling
- 8 Form 4 sale SRRKNo planApr 16 +93 days
Sold 30,615 shares at $49.57 ($1.5M)
Hallal David, Chief Executive Officer
No 10b5-1 planSold 1.8% of holdings ($82.8M position)1.6M shares leftFiling
Every transaction
Loading transactions…
Sales and notices (63)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | SRRK | Chief Executive Officer | Form 4 sale | 30,615 | $1.5M | 1.8% | No plan | SEC |
| Jan 13, 2026 | SRRK | Chief Executive Officer | Form 4 sale | 57,450 | $2.5M | 3.6% | No plan | SEC |
| Jun 6, 2025 | ITOS | Director | Form 4 sale | 114,682 | $1.2M | 100.0% | Routine | SEC |
| Oct 19, 2022 | ALVR | Director, 10% owner | Form 4 sale | 600,000 | $5.1M | 81.3% | Unusual | SEC |
| Sep 29, 2022 | ALVR | Director, 10% owner | Form 4 sale | 400,000 | $2.9M | 35.7% | Unusual | SEC |
| Jul 21, 2022 | ALVR | Director, 10% owner | Form 4 sale | 4,227 | $23k | 0.2% | Plan not stated | SEC |
| Jun 9, 2022 | ITOS | Director | Form 4 sale | 29,615 | $597k | 100.0% | Unusual | SEC |
| Jun 3, 2022 | ALVR | Director, 10% owner | Form 4 sale | 65,725 | $241k | 3.1% | Unusual | SEC |
| Apr 21, 2022 | ALVR | Director, 10% owner | Form 4 sale | 4,227 | $25k | 0.2% | Plan not stated | SEC |
| Mar 11, 2022 | ALVR | Director, 10% owner | Form 4 sale | 65,725 | $492k | 3.0% | Plan not stated | SEC |
| Jan 24, 2022 | ALVR | Director, 10% owner | Form 4 sale | 17,100 | $137k | 0.8% | Plan not stated | SEC |
| Dec 20, 2021 | ITOS | Director | Form 4 sale | 50,000 | $2.2M | 100.0% | Unusual | SEC |
| Aug 8, 2016 | ALEXION PHARMACEUTICALS INC | CEO | Form 4 sale | 332 | $46k | 0.2% | Plan not stated | SEC |
| Apr 1, 2016 | ALEXION PHARMACEUTICALS INC | CEO | Form 4 sale | 1,414 | $192k | 0.7% | Plan not stated | SEC |
| Feb 29, 2016 | ALEXION PHARMACEUTICALS INC | CEO | Form 4 sale | 2,014 | $280k | 1.0% | Plan not stated | SEC |
| Feb 8, 2016 | ALEXION PHARMACEUTICALS INC | CEO | Form 4 sale | 11,297 | $1.6M | 6.1% | Unusual | SEC |
| Aug 7, 2015 | ALEXION PHARMACEUTICALS INC | CEO | Form 4 sale | 329 | $63k | 0.2% | Plan not stated | SEC |
| Aug 4, 2015 | ALEXION PHARMACEUTICALS INC | CEO | Form 4 sale | 612 | $120k | 0.4% | Plan not stated | SEC |
| Mar 2, 2015 | ALEXION PHARMACEUTICALS INC | Chief Operating Officer | Form 4 sale | 730 | $132k | 0.5% | Plan not stated | SEC |
| Feb 10, 2015 | ALEXION PHARMACEUTICALS INC | Chief Operating Officer | Form 4 sale | 1,980 | $339k | 1.6% | Plan not stated | SEC |
| Feb 9, 2015 | ALEXION PHARMACEUTICALS INC | Chief Operating Officer | Form 4 sale | 2,920 | $508k | 2.3% | Plan not stated | SEC |
| Feb 4, 2015 | ALEXION PHARMACEUTICALS INC | Chief Operating Officer | Form 4 sale | 1,373 | $239k | 1.2% | Plan not stated | SEC |
| Dec 18, 2014 | ALEXION PHARMACEUTICALS INC | Chief Operating Officer | Form 4 sale | 5,494 | $1M | 4.6% | Plan not stated | SEC |
| Nov 3, 2014 | ALEXION PHARMACEUTICALS INC | Chief Operating Officer | Form 4 sale | 30,000 | $5.7M | 20.2% | Unusual | SEC |
| Aug 4, 2014 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 1,349 | $213k | 1.1% | Plan not stated | SEC |
| Feb 7, 2014 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 1,620 | $252k | 1.4% | Plan not stated | SEC |
| Feb 4, 2014 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 3,119 | $482k | 2.9% | Plan not stated | SEC |
| Jan 29, 2014 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 729 | $97k | 0.7% | Plan not stated | SEC |
| Dec 18, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 22,658 | $2.9M | 17.1% | Plan not stated | SEC |
| Dec 9, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 25,342 | $3.2M | 18.8% | Unusual | SEC |
| Oct 28, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 48,000 | $5.9M | 35.2% | Unusual | SEC |
| Aug 5, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 730 | $85k | 0.8% | Plan not stated | SEC |
| Jul 30, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 746 | $83k | 0.8% | Plan not stated | SEC |
| Jul 12, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 50,000 | $6M | 35.8% | Unusual | SEC |
| Feb 4, 2013 | ALEXION PHARMACEUTICALS INC | EVP, Chief Commercial Officer | Form 4 sale | 2,085 | $201k | 2.9% | Plan not stated | SEC |
| Jan 29, 2013 | ALEXION PHARMACEUTICALS INC | EVP. Global Commercial Ops | Form 4 sale | 1,144 | $108k | 1.6% | Plan not stated | SEC |
| Jul 31, 2012 | ALEXION PHARMACEUTICALS INC | SVP. Global Commercial Ops | Form 4 sale | 51,235 | $5.5M | 45.3% | Unusual | SEC |
| Jun 15, 2012 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 14,308 | $1.3M | 18.5% | Unusual | SEC |
| Feb 23, 2012 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 40,000 | $3.4M | 42.9% | Unusual | SEC |
| Jan 30, 2012 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 2,450 | $182k | 5.8% | Plan not stated | SEC |
| Jan 10, 2012 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 536 | $40k | 1.3% | Plan not stated | SEC |
| Nov 28, 2011 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 20,000 | $1.3M | 33.5% | Unusual | SEC |
| Jul 28, 2011 | ALEXION PHARMACEUTICALS INC | SVP. Global Commercial Ops | Form 4 sale | 37,427 | $2.1M | 55.7% | Unusual | SEC |
| Jul 11, 2011 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 501 | $25k | 1.6% | Plan not stated | SEC |
| Mar 3, 2011 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 5,000 | $496k | 24.2% | Unusual | SEC |
| Jan 27, 2011 | ALEXION PHARMACEUTICALS INC | SVP, Global Commerical Ops | Form 4 sale | 1,110 | $94k | 10.3% | Plan not stated | SEC |
| Jan 18, 2011 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 245 | $20k | 2.2% | Plan not stated | SEC |
| Jan 10, 2011 | ALEXION PHARMACEUTICALS INC | SVP, Global Commercial Ops | Form 4 sale | 269 | $22k | 2.4% | Plan not stated | SEC |
| Dec 15, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 13,616 | $1.1M | 60.8% | Unusual | SEC |
| Nov 4, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 22,619 | $1.6M | 85.7% | Unusual | SEC |
| Jul 16, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 227 | $12k | 3.4% | Plan not stated | SEC |
| Jul 12, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 238 | $12k | 3.5% | Plan not stated | SEC |
| Jun 21, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 916 | $50k | 11.8% | Plan not stated | SEC |
| Mar 2, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 10,000 | $518k | 56.3% | Unusual | SEC |
| Feb 16, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 6,242 | $299k | 44.5% | Unusual | SEC |
| Jan 19, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 227 | $11k | 2.8% | Plan not stated | SEC |
| Jan 11, 2010 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 1,088 | $52k | 11.7% | Plan not stated | SEC |
| Dec 21, 2009 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 916 | $44k | 8.9% | Plan not stated | SEC |
| Dec 11, 2009 | ALEXION PHARMACEUTICALS INC | SVP Commercial Ops, Americas | Form 4 sale | 10,000 | $464k | 49.4% | Unusual | SEC |
| Jul 27, 2009 | ALEXION PHARMACEUTICALS INC | Sr. VP Comm Ops, Americas | Form 4 sale | 8,640 | $372k | 45.8% | Unusual | SEC |
| Jul 16, 2009 | ALEXION PHARMACEUTICALS INC | Sr. VP Comm Ops, Americas | Form 4 sale | 238 | $9k | 1.2% | Plan not stated | SEC |
| Jun 19, 2009 | ALEXION PHARMACEUTICALS INC | Sr. VP Comm Ops, Americas | Form 4 sale | 789 | $30k | 4.0% | Plan not stated | SEC |
| Jun 11, 2009 | ALEXION PHARMACEUTICALS INC | Sr. VP Comm. Ops, Americas | Form 4 sale | 3,590 | $136k | 15.3% | Plan not stated | SEC |